Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

被引：1
|
作者：
El-Ghazzi, Nathan [1 ]
Lavaud, Pernelle [2 ]
机构：
[1] Univ Clermont Auvergne, Med Oncol Serv, Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 03期
关键词：
Non-small-cell lung carcinoma; Immunotherapy; Checkpoint immune inhibitors; Chemotherapy; PLATINUM-DOUBLET CHEMOTHERAPY; PLUS IPILIMUMAB;
D O I：
10.1016/j.bulcan.2021.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 233
页数：4
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [2] First-Line Nivolumab Plus Ipilimumab versus Chemotherapy in NSCLC
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 465 - 465
  • [3] Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
    Remon, Jordi
    Esteller, Laura
    Taus, Alvaro
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4893 - 4904
  • [4] Metastatic Melanoma Nivolumab plus Ipilimumab is the better First-line Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 448 - 449
  • [5] CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
    Antonia, Scott J.
    Gettinger, Scott N.
    Goldman, Jonathan
    Brahmer, Julie
    Borghaei, Hossein
    Chow, Laura Q.
    Ready, Neal E.
    Gerber, David E.
    Juergens, Rosalyn
    Shepherd, Frances
    Laurie, Scott A.
    Young, Tina
    Geese, William J.
    Agrawal, Shruti
    Li, Xuemei
    Hellmann, Matthew D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S250 - S251
  • [6] The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial
    Juloori, A.
    Bestvina, C. M.
    Pointer, K. B.
    Pitroda, S. P.
    Abazeed, M. E.
    Katipally, R. R.
    Sivananthan, A. P.
    Hoffman, P. C.
    Mohammed, T.
    Rayani, S.
    Rampurwala, M.
    Narula, S.
    Garassino, M. C.
    Weichselbaum, R. R.
    Vokes, E. E.
    Patel, J. D.
    Chmura, S. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S95 - S96
  • [7] First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC : The Updated Outcomes From CheckMate 9LA
    Zhao, Binghao
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E101 - E102
  • [8] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [9] Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1513): : 4 - 5
  • [10] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    Socinski, M. A.
    Jotte, R. M.
    Cappuzzo, F.
    Orlandi, F.
    Stroyakovskiy, D.
    Nogami, N.
    Rodriguez-Abreu, D.
    Moro-Sibilot, D.
    Thomas, C. A.
    Barlesi, F.
    Finley, G.
    Kelsch, C.
    Lee, A.
    Coleman, S.
    Deng, Y.
    Shen, Y.
    Kowanetz, M.
    Lopez-Chavez, A.
    Sandler, A.
    Reck, M.
    Ahualli, A.
    Jarchum, G.
    Kaen, D. L.
    Kahl, S.
    Kotliar, M.
    Kowalyszyn, R. D.
    Lerzo, G.
    Magri, I
    Martin, C.
    Pastor, A.
    Picon, P.
    Streich, G.
    Varela, M.
    Blinman, P.
    Boyer, M.
    Crombie, C.
    Gauden, S.
    Gill, S.
    Hughes, B.
    John, T.
    Joshi, A.
    Kosmider, S.
    Lewis, C.
    Millward, M.
    Nordman, I
    Nott, L.
    O'Byrne, K.
    Parnis, F.
    Potasz, N.
    Richardson, G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24): : 2288 - 2301
12345